Spearheading Immunotherapies

Harpoon is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that unleash the natural power of the T cells to fight cancer and other diseases.

At the heart of Harpoon’s approach is a novel antibody-derived platform called TriTAC® (Tri-specific T cell Activating Construct) designed for targeted penetration and destruction of solid tumors and hematologic malignancies, and engineered to bind to human serum albumin for improved therapeutic schedule and patient convenience.

Management Team

Board of Directors

Scientific Advisory Board


Our Partners

In November 2019, Harpoon and Abbvie entered into an exclusive worldwide option and license transaction for HPN217, Harpoon’s B cell maturation antigen (BCMA)-targeting Tri-specific T cell Activating Construct (TriTAC®), and an expansion of their existing discovery collaboration for up to six additional targets. These agreements build upon the discovery collaboration established by the two companies in October 2017 and are expected to advance and broaden the use of Harpoon’s proprietary TriTAC platform. The TriTAC platform produces novel T cell engagers targeting both solid tumors and hematologic malignancies.